Erratum

Article Outline

• Copyright

In “Donor and Recipient CMV Serostatus and Outcome of Pediatric Allogeneic HSCT for Acute Leukemia in the Era of CMV-Preemptive Therapy” (Behrendt et al, Biol Blood Marrow Transplant 2009:15(1): 54-60), there were incomplete row labels in Table 1. The corrected Table 1 is as follows:

Table 1. Baseline Characteristics of Pediatric HSCT Recipients (n=140), Overall and By CMV Serostatus of Donor/Recipient.

	Overall N=140	D-/R- Graft N=35	Other Graft N=105
	N (%)	N (%)	N (%)
Male	78 (55.7)	20 (57.1)	58 (55.2)
Diagnosis
ALL	81 (57.9)	18 (51.4)	63 (60.0)
AML	54 (38.6)	16 (45.7)	38 (36.2)
MDS	5 (3.6)	1 (2.9)	4 (3.8)
Disease Stage
Early	49 (35.0)	14 (40.0)	35 (33.3)
Intermediate	81 (57.9)	19 (54.3)	62 (59.1)
Advanced	10 (7.1)	2 (5.7)	8 (7.6)
Ethnicity
Hispanic White	65 (46.4)	11 (31.4)	54 (51.4)
Non-Hispanic White	56 (40.0)	20 (57.1)	36 (34.3)
Asian	13 (9.3)	2 (5.7)	11 (10.5)
African-American	6 (4.3)	2 (5.7)	4 (3.8)
Donor Type
Sibling	78 (55.7)	23 (65.7)	55 (52.4)
Unrelated	62 (44.3)	12 (34.3)	50 (47.6)
Donor Age
0-19 Years	74 (52.9)	23 (65.7)	51 (48.6)
20-39 Years	43 (30.7)	8 (22.9)	35 (33.3)
40-55 Years	23 (16.4)	4 (11.4)	19 (18.1)
Graft Source
Bone Marrow	77 (55.0)	18 (51.4)	59 (56.2)
Peripheral Blood	63 (45.0)	17 (48.6)	46 (43.8)
Year of Transplantation
1997-2002	69 (49.3)	18 (51.4)	51 (48.6)
2003-2007	71 (50.7)	17 (48.6)	54 (51.4)
Female-to-Male Graft
Yes	32 (22.9)	8 (22.9)	24 (22.9)
No	108 (77.1)	27 (77.1)	81 (77.1)
Conditioning Regimen
∗TBI + Etoposide	74 (52.9)	17 (48.6)	57 (54.3)
∗TBI + Cy	45 (32.1)	12 (34.3)	33 (31.4)
Busulfan + Cy	21 (15.0)	6 (17.1)	15 (14.3)
GVHD Prophylaxis
Cyclosporine + MTX	81 (57.9)	24 (68.6)	57 (54.3)
Tacrolimus (±other)	51 (36.4)	11 (31.4)	40 (38.1)
Cyclosporine ± MMF	8 (5.7)	0	8 (7.6)

∗ TBI indicates total body irradiation, delivered in fractionated doses in 116/119 cases; HSCT, hematopoietic stem cell transplantation; CMV, cytomegalovirus; ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; MDS, myelodysplastic syndromes; GVHD, graft-versus-host disease; Cy, cyclophosphamide; MTX, methotrexate; MMF mycophenolate mofetil.